4.8 Article

Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study

Journal

FRONTIERS IN IMMUNOLOGY
Volume 9, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2018.02706

Keywords

teriflunomide; pregnancy-related outcomes; nationwide Danish register study; teriflunomide treated men and women; pregnancy-related outcomes for mother and child

Categories

Funding

  1. Sanofi Genzyme Denmark

Ask authors/readers for more resources

Background: The majority of persons diagnosed with multiple sclerosis (MS) experience their first MS symptoms in the reproductive age. Teriflunomide (TFL, Aubagio), was first released in Denmark for relapsing-remitting MS in December 2013. TFL treatment is contraindicated in women of childbearing potential who are not using reliable contraception. TFL can be transmitted via semen and a low risk of male-mediated embryo-fetal toxicity is described. Objective: To report pregnancy outcomes of TFL-treated women and partners to TFL-treated men: gestation week. Methods: Prospective cohort study comparing pregnancy outcomes of TFL-treated men and women, matched on age at conception, 1: 4 with controls from the general population. Data on TFL-treated patients treated 1st of January 2014-31st of December 2016 for at least 30 consecutive days prior to conception, and with conception occurring latest 2 years after treatment discontinuation were extracted from The Danish Multiple Sclerosis Registry and merged with several national reproductive registries. Logistic regression was used to analyse the association between TFL exposure and any adverse event. Results: A total of 31 pregnancies were recorded, 13 women and 18 of partners to a TFL-treated man. All 18 partners of TFL-treated men completed their pregnancies: livebirth (18), gestation time > 37 weeks (17), gestation time 33-36 weeks (1), normal birth weight (18), spontaneous and elective abortion (0), congenital malformation (plagiocephali) (1), normal delivery (14), induced delivery (2), cesarean section (2), Apgar score >= 7 (18). Among the 13 pregnancies in women exposed to TFL: elective abortion (11), spontaneous abortion (0), livebirth (2), gestation time > 37 weeks (2), normal birth weight (2), congenital malformations (0), normal delivery (1), induced delivery (1), Apgar score >= 7 (2). The TFL group was associated with a 22% reduction in the odds of any adverse event relative to controls, although this association was not significant (OR 0.78; 95% CI 0.16-3.72, p = 0.753). Conclusion: Pregnancy outcomes were consistent with those of the general population. The malformation reported of the partner to a TFL-treated man is comparable to the rate of plagiocephaly reported in Denmark.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Rheumatology

Response to: 'Neuroinflammatory events after anti-TNFα therapy' by Kaltsonoudis et al

Tine Iskov Kopp, Benedicte Delcoigne, Elizabeth Arkema, Melinda Magyari, Henning Locht, Finn Thorup Sellebjerg, Rene Lindholm Cordtz, Dorte Jensen, Johan Askling, Lene Dreyer

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Clinical Neurology

Hormone therapy and disease activity in Danish women with multiple sclerosis: A population-based cohort study

Tine Iskov Kopp, Ojvind Lidegaard, Melinda Magyari

Summary: This Danish cohort study investigated the association between hormone therapy (HT) and disease activity and disability accrual among women with multiple sclerosis (MS). The study found no significant association between HT and disability accrual, although there was a trend for increased risk with longer duration of use. However, current users of HT had a 20% increased risk of recurrent relapse compared to non-users.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Review Clinical Neurology

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, Maria Pia Amato, Tobias Derfuss, Franziska Di Pauli, Ellen Iacobaeus, Marcin Mycko, Hesham Abboud, Anat Achiron, Angelo Bellinvia, Alexey Boyko, Jean-Laurent Casanova, David Clifford, Ruth Dobson, Mauricio F. Farez, Massimo Filippi, Kathryn C. Fitzgerald, Mattia Fonderico, Riadh Gouider, Yael Hacohen, Kerstin Hellwig, Bernhard Hemmer, Ludwig Kappos, Filipa Ladeira, Christine Lebrun-Frenay, Celine Louapre, Melinda Magyari, Matthias Mehling, Celia Oreja-Guevara, Lekha Pandit, Caroline Papeix, Fredrik Piehl, Emilio Portaccio, Isabel Ruiz-Camps, Krzysztof Selmaj, Steve Simpson-Yap, Aksel Siva, Per Soelberg Sorensen, Maria Pia Sormani, Maria Trojano, Adi Vaknin-Dembinsky, Sandra Vukusic, Brian Weinshenker, Heinz Wiendl, Alexander Winkelmann, Maria Isabel Zuluaga Rodas, Mar Tintore, Bruno Stankoff

Summary: In recent years, there have been rapid developments in the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), with a wide range of disease-modifying treatments (DMTs) now available. However, most DMTs come with the risk of adverse events, particularly infections. To address this, an international workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was held in April 2021 to review the current knowledge on infection risks associated with DMT use in MS and NMOSD patients, and to discuss strategies for risk mitigation. The workshop also explored specific populations, such as children, pregnant women, individuals with comorbidities, and those living in regions with high infection burden, as well as the impact of the ongoing SARS-CoV-2 pandemic on DMT-associated infectious risks.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES)

Morten Riemenschneider, Lars G. Hvid, Steffen Ringgaard, Mikkel Karl Emil Nygaard, Simon Fristed Eskildsen, Tobias Gaemelke, Melinda Magyari, Henrik Boye Jensen, Helle Hvilsted Nielsen, Matthias Kant, Masoud Falah, Thor Petersen, Egon Stenager, Ulrik Dalgas

Summary: Early supervised aerobic exercise did not reduce relapse rate or global brain atrophy in patients with MS, but it positively affected the microstructural integrity of important motor-related tracts and nuclei.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Computer Science, Artificial Intelligence

Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder

Shuo Liu, Jing Han, Estela Laporta Puyal, Spyridon Kontaxis, Shaoxiong Sun, Patrick Locatelli, Judith Dineley, Florian B. Pokorny, Gloria Dalla Costa, Letizia Leocani, Ana Isabel Guerrero, Carlos Nos, Ana Zabalza, Per Soelberg Sorensen, Mathias Buron, Melinda Magyari, Yatharth Ranjan, Zulqarnain Rashid, Pauline Conde, Callum Stewart, Amos A. Folarin, Richard J. B. Dobson, Raquel Bailon, Srinivasan Vairavan, Nicholas Cummins, Vaibhav A. Narayan, Matthew Hotopf, Giancarlo Comi, Bjoern Schuller

Summary: This study introduces a contrastive convolutional auto-encoder (contrastive CAE) to identify potential COVID-19 infection in participants with multiple sclerosis (MS) based on heart-rate data, achieving high classification performance with effective symptom detection and low false alarm rate.

PATTERN RECOGNITION (2022)

Article Clinical Neurology

Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population

Johanna Balslev Andersen, Malthe Faurschou Wandall-Holm, Melinda Magyari

Summary: The study investigated the association of adverse perinatal outcomes in newborns with maternal or paternal exposure to teriflunomide, and found no increased prevalence of spontaneous abortion, preterm birth, congenital malformations, low Apgar score, or being small for gestational age in newborns with exposure to teriflunomide compared to the general population.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Article Clinical Neurology

Aging With Multiple Sclerosis: Age-Related Factors and Socioeconomic Risks

Malthe Faurschou Wandall-Holm, Mads Albrecht Andersen, Mathias Due Buron, Melinda Magyari

Summary: Danish patients with MS are at a higher risk of losing all income from earnings and at a much higher risk of receiving disability pension compared with healthy controls.

FRONTIERS IN NEUROLOGY (2022)

Article Clinical Neurology

Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis

Johanna Balslev Andersen, Finn Sellebjerg, Melinda Magyari

Summary: This study found no increased association of adverse pregnancy outcomes in newborns with fetal exposure to disease-modifying drugs (DMDs) when compared with either DMD-unexposed pregnancies or the general population.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

Alessio Signori, Johannes Lorscheider, Sandra Vukusic, Maria Trojano, Pietro Iaffaldano, Jan Hillert, Robert Hyde, Fabio Pellegrini, Melinda Magyari, Nils Koch-Henriksen, Per Soelberg Sorensen, Tim Spelman, Anneke van Der Walt, Dana Horakova, Eva Havrdova, Marc Girard, Sara Eichau, Francois Grand'Maison, Oliver Gerlach, Murat Terzi, Serkan Ozakbas, Olga Skibina, Vincent Van Pesch, Maria Jose Sa, Julie Prevost, Raed Alroughani, Pamela A. McCombe, Riadh Gouider, Saloua Mrabet, Tamara Castillo-Trivino, Chao Zhu, Koen de Gans, Jose Luis Sanchez-Menoyo, Bassem Yamout, Samia Khoury, Maria Pia Sormani, Tomas Kalincik, Helmut Butzkueven

Summary: This study identifies different subgroups of patients with secondary progressive multiple sclerosis (SPMS) based on their longitudinal trajectories of disability. The findings suggest that SPMS patients progress at greatly different rates and the identification of distinct trajectories can guide better patient selection in future clinical trials. Additionally, the distinct trajectories may reflect heterogeneous pathological mechanisms of progression.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Real-world operation of multiple sclerosis centres in Central-Eastern European countries covering 107 million inhabitants

Zsofia Kokas, Anett Jardanhazy, Daniel Sandi, Tamas Biernacki, Zsanett Fricska-Nagy, Judit Fuvesi, Halina Bartosik-Psujek, Vanja Basic Kes, Thomas Berger, Achim Berthele, Jelena Drulovic, Bernhard Hemmer, Dana Horakova, Alenka Horvat Ledinek, Eva Kubala Havrdova, Melinda Magyari, Konrad Rejdak, Cristina Tiu, Peter Turcani, Peter Klivenyi, Zsigmond Tamas Kincses, Laszlo Vecsei, Krisztina Bencsik

Summary: In most Central-Eastern European countries, the recommendations for multiple sclerosis (MS) care units are met, but there are still some deficiencies, such as the lack of speech therapists, specialists for continence, pain and spasticity, neuro-ophthalmologists, and otoneurologists. Although multiple disease-modifying therapies (DMTs) are reimbursed, not every center provides all available DMTs. Additionally, only Austria and the Czech Republic require national registry use. Therefore, in countries where MSCU recommendations are not fulfilled, a strictly regulated center system similar to the Austrian and Czech model, with a registry-based quality control, may ensure appropriate care for MS patients.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS

Nils Iorgen Koch-Henriksen, Lau Caspar Thygesen, Per Soelberg Sorensen, Melinda Magyari

Summary: This study demonstrates the use of instrumental variables to reduce bias in observational studies and confirms the effectiveness of treatment in delaying disability in multiple sclerosis.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Chemistry, Analytical

Automatic Assessment of the 2-Minute Walk Distance for Remote Monitoring of People with Multiple Sclerosis

Spyridon Kontaxis, Estela Laporta, Esther Garcia, Matteo Martinis, Letizia Leocani, Lucia Roselli, Mathias Due Buron, Ana Isabel Guerrero, Ana Zabala, Nicholas Cummins, Srinivasan Vairavan, Matthew Hotopf, Richard J. B. A. Dobson, Vaibhav Narayan, Maria Libera La Porta, Gloria Dalla Costa, Melinda Magyari, Per Soelberg Sorensen, Carlos Nos, Raquel Bailon, Giancarlo Comi, RADAR CNS Consortium

Summary: The aim of this study was to investigate the feasibility of automatically assessing the 2-Minute Walk Distance (2MWD) for monitoring people with multiple sclerosis (pwMS). The study collected the 2MWDs as evaluated by clinicians and derived from accelerometer data from 154 pwMS, along with MS-related clinical outcomes. The results showed that estimating the 2MWD using a wearable device yielded a low error rate and had strong correlations with clinical outcomes.

SENSORS (2023)

Article Clinical Neurology

Interferon-beta exposure in-utero and the risk of infections in early childhood

Josefine Windfeld-Mathiasen, Henrik Horwitz, Johanna Balslev Andersen, Elisabeth Framke, Christina Gade, Jon Traerup Andersen, Melinda Magyari

Summary: This retrospective matched cohort study investigated the impact of exposure to interferon-beta during pregnancy on the risk of significant infections in early childhood. The study included 510 children born to mothers with multiple sclerosis who were exposed to interferon-beta in utero. The results showed that exposure to interferon-beta had little to no impact on the risk of acquiring significant infections during the first five years of childhood.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

COVID-19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark

Dominika Stastna, Frederik Elberling, Luigi Pontieri, Elisabeth Framke, Dana Horakova, Jiri Drahota, Petra Nytrova, Melinda Magyari

Summary: This study evaluated the difference in relapse occurrence pre- and post-COVID-19 vaccination in Danish patients with relapsing multiple sclerosis. The findings showed that there was no significant increase in relapse activity following the administration of the first dose of the COVID-19 vaccine.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe

Richard Nicholas, Jeff Rodgers, James Witts, Annalaura Lerede, Tim Friede, Jan Hillert, Lars Forsberg, Anna Glaser, Ali Manouchehrinia, Ryan Ramanujam, Tim Spelman, Pernilla Klyve, Jiri Drahota, Dana Horakova, Hanna Joensen, Luigi Pontieri, Melinda Magyari, David Ellenberger, Alexander Stahmann, Helmut Butzkueven, Anneke Van der Walt, Vladimir Bezlyak, Carol Lines, Rod Middleton

Summary: This study analyzed registry data from multiple countries and found variations in DMT usage, with factors such as gender, disability level, and monitoring influencing the likelihood of receiving DMTs. The study also explored the impact of diagnosis on DMT usage in clinical SPMS.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

No Data Available